



TARGETED ALPHA IMMUNOTHERAPY

« *ASTATINE AGAINST CANCER* »



ATONCO – MATWIN, Bordeaux May 2024

Sylvain Fanier - President CEO



Atonco

Bladder Cancer

10

Cancer worldwide - 6th in Men



573,000 new cases / year

213.000 deaths / year






First line therapy: BCG + Chemo

40% relapse - High toxicity

> 100.000 Radical Cystectomy / Year

... calling for the emergence of new therapy





At-211 - Next generation of Radiotherapeutics (vs emerging Ac-225)

❖ Stable targets and shorter half live (7.2h)

- ✓ Easier and safer production
- ✓ Preserve the rivers and the planet
- ✓ Larger and easier patient care

ATO-101™ COMPONENTS

Antibody Anti-CAIX
Girentuximab

+

At-211 Radiolabeling patented
method

+

Bladder cancer expressing antigen
carbonic anhydrase IX (CAIX).

PROPRIETARY IP

Telix Pharmaceuticals TLX250 Patent
WW Licence (GMP Ready)

+


Nantes University Patent
WW sub-licence (GMP ready)

+

Molecules and Methods
WW Patent



TEAM, EXPERTS AND PARTNERS



TEAM ATONCO



Laurette Fisson



Denis Bilodeau



Aurélie Moreau



Adrien Reymond




Clément Mayeur



Sylvain Fanier



JF Chatal



Jean-Pierre Cabocel



Mario Campone



Jacques Barbet



Jean-Marc Ledoussal

SCIENTIFIC ADVISORY BOARD

PHARMACEUTICAL PRODUCTION GMP



DEVPT CMC ATO-101



PRODUCTION ATO-101 RADIOPHARMACEUTICAL GMP



EU CLINICAL RESEARCH CENTERS - PRINCIPAL INVESTIGATORS (PI)



Caroline Rousseau, MD, PhD
Head of Nuclear Medicine
Nantes, France



Ulla Norström Joessen, MD, PhD
Associate Clinical Professor
Department of Clinical Medicine
Urology
Copenhagen, Denmark



US CLINICAL RESEARCH CENTER - PRINCIPAL INVESTIGATOR (PI)



Benjamin Viglianti, MD, PhD
Associate Clinical Professor of
Radiology
Head of Nuclear Medicine
Ann Arbor Michigan, MI, USA





ATO-101™ MARKET



INDICATION

NMIBC PATIENT REFRACTORY TO BCG THERAPY AND CANDIDATE TO COMPLETE CYSTECTOMY



ADRESSABLE MARKET

37.000 Patients



MARKET SHARE OBJECTIVE

22%

SALES PROJECTION OBJECTIVES /4th YEAR Post MA (Marketing Authorization)

SALES	DOSES/YEAR	UNIT COGS (USD)	COGS (USDM)	UNIT PRICE (USD)	SALES (USDM)	GROS MARGIN
EU	3 000	6 000	18	30 000	90	80%
US	5 000	7 000	35	70 000	350	90%
TOTAL	8 000	6 625	53	55 000	440	88%




OPPORTUNITY



> USD 430M ATO-101 Sales /year

> 8,000 patients/year



MAY 2024 ACHIEVEMENTS

- Preclinical studies
- PERTINENCE clinical study
6 Patients - CA-IX-Zr89
 - NO TOXICITY
 - HIGH AFFINITY (84%)
- GMP Developments ATO-101
- CMC and Clinical Partnerships

SERIES A USE OF FUNDS: €15M - Q4 2024

- US Phase 1/2b (70 patients with single-dose instillation).
- EU Phase 1 (20 Patients with fractionated-dose instillation)
- Partnering for Cyclotron Astate-211 to secure long term supply via in house manufacturing and preserve drug profitability

(MA: MARKETING AUTHORIZATION)



Atonco



THANK YOU !

CONTACT

Sylvain Fanier, President CEO

Telephone: +33 6 07 59 01 67

E-mail: sylvain.fanier@atonco-pharma.com

www.atonco-pharma.com